COX-2 selective inhibitors on severe market competition.

A new NSAID drug market has shown a severe competition on the market led by 4 major COX-2 selective inhibitors including Celebrex by Pharmacia/Pfizer, Vioxx by MSD and Mobic by Boehringer Ingelheim.

Especially Celebrex and Vioxx severe competed each other, focusing their marketing strategies on adverse reactions rather than already well proven efficacies and therapeutic indications.

Pharm...